4/6/2023 0 Comments PraxbindAdditionally, the ongoing RE-VECTO program evaluates usage patterns of Praxbind in the clinical practice setting. The final results of this study were published in the New England Journal of Medicine in July 2017. The safety and efficacy of Praxbind in reversing the anticoagulant effect of Pradaxa has been demonstrated through the phase III RE-VERSE AD study, the largest study to investigate a reversal agent for a NOAC. It is highly specific to Pradaxa and offered in a hospital in one, ready-to-administer dose for all Pradaxa patients. Praxbind is the first and only specific reversal agent for a novel oral anticoagulant (NOAC), and provides immediate reversal of the anticoagulant effect of Pradaxa. Food and Drug Administration approved Praxbind as a specific reversal agent for Pradaxa in October 2015 under accelerated approval-followed by full approval in April 2018-for use in the event of an urgent procedure/emergency surgery or uncontrollable/life-threatening bleeding. “We hope patients are reassured in knowing that a specific reversal agent for a NOAC is widely available.” “Emergency situations are unpredictable and access to a reversal agent is important for the rare events when the anticoagulant effect of Pradaxa must be reversed,” said Thomas Seck, vice president, clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. where Praxbind is stocked by using a zip code locator tool available at. Healthcare providers and patients can quickly search for institutions in the U.S. This represents a significant increase in the availability of Praxbind since March 2016, when it was stocked in 2,200 institutions. Boehringer Ingelheim announced that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |